Home  >  Product Launches
Product Launches
+ Font Resize -

Dr Reddy's Labs launches generic sofosbuvir & velpatasvir tablets for HCV in India

Our Bureau, Mumbai
Monday, May 15, 2017, 17:20 Hrs  [IST]

Dr Reddy’s Laboratories has launched the generic version of sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, under a brand name Resof Total, in India.

Dr Reddy’s Resof Total tablets are available in bottle count size of 28.  

Resof Total is used for the treatment of adult patients with chronic hepatitis C virus, genotype 1,2,3,4,5 or 6 infection  - without Cirrhosis or with compensated cirrhosis;  - with decompensated cirrhosis for use in combination with Ribavirin.

The sofosbuvir 400mg and velpatasvir 100mg fixed-dose combination is a generic version of Gilead’s brand Epclusa. treatment with this combination achieves a cure rate of more than 90% in all genotypes of hepatitis C virus (1,23,4, or 6). Achievement of higher cure rate with this combination in hepatitis C genotype 3 addresses a significant unmet need, since infection with genotype 3 of hepatitis C is upto 70% in Indian patients infected with hepatitis C.

 

Post Your commentsPOST YOUR COMMENT
Comments
* Name :     
* Email :   
  Website :  
   
     
Khushbu Bhavsar Sep 24, 2017 1:28 PM
what are the benefits of using combination of sofosbuvir and velpatasvir over any other tripple combiation like sofo+vepa+ribavirin or sofo+velpa+voxilaprevir?
 
IPJPI_150x60en_2017
acssymposium
CPhI-WWW-150x60-stat-v1
PHARMACONNECT_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |